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Normal liver is made of various
epithelial and mesenchymal cells,
and benign lesions may develop
from each of these cells. Benign pro-
liferation of the hepatocytes leads to
hepatocellular adenoma (HA) and to
focal nodular hyperplasia (FNH), in
which there is also biliary structure
proliferation. These hepatocellular
lesions are much rarer than hepatic
hemangioma, which develops from
endothelial cells, and cysts of con-
genital and developmental origin,
which constitute the most common
benign liver lesions. Benign liver
tumors and tumorlike conditions are
now being more frequently detected
due to the widespread use of imag-
ing modalities particularly ultra-
sonography (US). Characterization
of these lesions by imaging is
important for exclusion of malig-
nant neoplasms and for avoidance
of unnecessary invasive procedures.
Spiral computed tomography (CT)
and/or magnetic resonance (MR)
imaging play a major role for these
evaluations, using state of the art
techniques including optimization of
parameters and use of dedicated
contrast agents. Then, the role of
guided biopsies is actually limited
for this purpose.
Hemangioma
Hemangioma is a benign focal
hepatic lesion that consists of
blood-filled spaces lined by single
layer of flat endothelial cells (1).
Blood flows slowly within these
spaces. Areas of thrombosis, fibro-
sis, haemorrhage and calcifications
are sometimes encountered within
large hemangiomas (2,3). The
lesions are clinically silent (4).
Hemangiomas remain constant in
size over time particularly when
they are less than 4 cm in diameter. 
On US, the typical hemangioma
appears as a well defined, homoge-
neous, and hyperechoic lesion with
posterior acoustical enhancement.
The lesions are usually located close
to the liver surface or to hepatic
veins. Atypical features on US
include hypoechogenicity (especial-
ly in hemangioma located in a fatty
liver), mixed echogenicity, and
peripheral halo (7). The majority of
hemangiomas show no signal on
color-coded Doppler US (8). On CT,
hemangioma appears hypodense to
the liver before injection of iodinat-
ed contrast medium and its attenua-
tion value is similar to that of blood
in adjacent blood vessels. On spiral
CT, hemangioma shows enhance-
ment starting at the periphery as a
discontinuous nodular enhance-
ment, particularly observed at the
arterial phase, and progressing with
or without complete fill-in and per-
sistent enhancement on delayed
imaging (9) (Fig. 1). Difficulties on
CT diagnosis of hemangioma arise
when the lesions are too small to
show the classical enhancement
patterns or when hemangiomas
appears hypervasular and homoge-
neous at the arterial phase, mimick-
ing a benign hepatocellular tumors;
these latter presentations are more
and more frequently observed,
using thin collimations on spiral CT,
as well as some more rare unen-
hanced hypovascular heman-
giomas. At the arterial phase, tran-
sient hepatic attenuation differences
can be oserved just close to these
hypervascular hemangiomas relat-
ed to small arterioportal shunts
(Fig. 2, 3). MR imaging is now con-
sidered the best imaging method for
characterization of hemangioma
which appears as a homogeneous
well defined lesion, hypointense on
T1-weighted images, and extremely
hyperintense on heavily T2-weight-
ed images. Two types of internal
areas may be observed: thrombosis
is marked by hypointense band and
myxoid transformation or presence
of a loose connective tissue, usually
observed in large hemangiomas, by
hyperintense areas within the
hemangioma (Fig. 4). On dynamic
gadolinium-enhanced MR, heman-
gioma shows peripheral nodular
enhancement progressing cen-
tripetally to uniform homogeneous
enhancement. Differentiation of
metastases from hemangioma is of
utmost importance particularly
when a focal hepatic lesion is inci-
dentally discovered in a patient with
a known primary malignancy.
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Fig. 1. — Liver hemangioma. Peripheral and discontinous
globular enhancement at the arterial phase, on spiral CT.
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Metastases are usually less hyperin-
tense than hemangioma on T2-
weighted images and this difference
in signal intensity increases on
increasing TEs. Besides, metastases
do not show the characteristic
enhancement patterns of heman-
gioma on dynamic gadolinium-
enhanced MR imaging (11, 13).
Hypervascular metastases were
shown to have the following charac-
teristics: - ring enhancement most
intense and continuous at early
phase,- washout of contrast materi-
al, resulting in heterogeneous inten-
sity, with peripheral washout a com-
mon appearance,- uniform thickness
of the enhanced ring, or jagged
inner enhanced margins. The
enhancement pattern of liver
lesions on the immediate post-
gadolinium images is the most use-
ful feature to distinguish between
hemangiomas and hypervascular
metastases or hepatocellular carci-
nomas (HCCs) in cirrhotic patient.
On MR imaging, atypical features of
hemangioma are less frequently
encountered than on CT or US
(Fig. 5). A typical moderate signal
intensity on T2-weighted images
associated with atypical poor
enhancement on the delayed post-
contrast images may be observed in
Fig. 2. — Hypervascular liver hemangioma.Transient hepatic
attenuation differences (THADs) close to hypervascular and
subcapsular hemangioma, located in segment III, related to
arterioportal shunts.
Fig. 3A and B. —Hypervascular hemangiomas in subcapsular
location.THADs are more obvious than the lesion itself.
B
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Fig. 4. — Cavernous hemangiomas with myxoid transforma-
tion. The bright areas within the hemangiomas are related to
the high water content of these areas, on long TR-long TE
weighted MR images (TE = 150 msec).
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rare forms of sclerosed heman-
giomas (14). It is only in such rare
cases of atypical hemangioma on
MR that imaging-guided fine needle
biopsy is resorted to as a final prob-
lem-solving method. In spite of
early warning reports, the technique
is considered by some authors to be
safe and accurate (15). The role of
specific MR contrast agents is limit-
ed because these lesions have no
hepatocyte nor Kupffer cells.
However a T1-effect can be present
using reticuloendothelial agents in
hemangiomas particularly in small
lesions due to a vascular effect
(Fig. 6).
Fig. 5A-C. — Atypical cavernous hemangioma of the left lobe,
atypiae marked by calcifications due to sclerosed areas.
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Fig. 6. — Liver hemangioma.On T2-weighted images, the
lesion, located in segment V, is hyperintense (A). On T1-WI
image, the lesion is isointense (B), and appears hyperintense
related to the surrounding liver after SPIO particles injection,
due to a vascular effect.
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Focal nodular hyperplasia
Focal nodular hyperplasia (FNH)
is a benign tumorlike condition
which is thought to be a hyperplas-
tic response to a local increase in
blood flow rather than a true neo-
plasm (28). FNH is a well circum-
scribed noncapsulated lesion, It has
usually a central stellate-shaped
scar with incomplete peripherally
radiating septa. The lesion is com-
posed of normal hepatocytes
arranged in nodules or thick layers
and separated by thin fibrous septa.
Arterial vessels are seen within the
scar and they demonstrate intimal
and medial fibromuscular hyperpla-
sia. Kupffer cells within the lesion
and biliary canaliculi within the
fibrous septa are also seen. The
lesion occurs predominantly in
young females. Recently, our group
has demonstrated that neither the
type of oral contraceptives nor the
duration can influence the size or
the number of FNH lesions (29,30).
During the follow-up, modifications
of size were observed in only 4 % of
studied patients with FNH, whatever
continuation or discontinuation of
low-dose oral contraceptives intake.
The clinical course is usually silent,
and the lesions are usually discov-
ered incidentally. Complications of
FNH are rare and then, this lesion
may require only conservative man-
agement if the diagnosis is done. 
On US, the echogenicity of FNH is
variable (31). The scar may be
demonstrated as a central small
area of altered echogenecity. The
lesion may be recognized only by its
displacement or indentation of the
adjacent veins, bulging of the hepat-
ic contours, or subtle modification
of the hepatic echopatterns. Color
Doppler US may demonstrate the
arterial vessels within the central
scar (32). On spiral (CT), FNH
appears isodense or slightly hypo-
dense in the precontrast scan. After
intravenous bolus injection of con-
trast medium, marked enhancement
is observed in the arterial phase
(Fig. 7) (31, 33). The lesion becomes
isodense in the portal phase and on
the delayed images. The scar
appears hypodense to the lesion in
the precontrast and the early post-
contrast images. On delayed
images, the scar appears iso or
hyperdense. Usually, the supplying
artery can be visualized within the
scar in the arterial phase (31, 33). On
MR imaging, FNH appears typically
isointense or slightly hypointense
on T1-weighted images and slightly
hyperintense on T2-weighted
images (Fig. 8). The scar appears
hypointense to the lesion on T1-
weighted images and hyperintense
on T2-weighted images. Flow-sensi-
tive MR sequences can be used to
demonstrate intralesional arteries,
particularly when these are unusual-
ly large. On dynamic MR imaging
performed after intravenous bolus
injection of extracellular contrast
agents such as gadolinium-DTPA
and gadolinium-DOTA, FNH
becomes rapidly hyperintense in the
arterial phase and then appears
isointense or slightly hyperintense
in the portal phase and on the
delayed images, without capsule
(Fig. 9). The central scar, appears
unenhanced in the early images and
hyperintense on the delayed images
(34-36). On superparamagnetic iron
oxide-enhanced T2-weighted MR
imaging, FNH shows loss of signal
due to the presence of Kupffer cells
within the lesion. On MR images
enhanced with hepatobiliary con-
trast agents such as manganese-
DPDP, uptake of the contrast agents
by FNH has been demonstrated due
to their content of hepatocytes (Fig.
10). MR imaging is currently one of
the best modalities for detection
and characterization of FNH, with a
sensitivity equal to 82% and a speci-
ficity reaching 100% in women,
according to strict criteria including:
(a)- homogeneity of the lesion,
(b)- slightly hyperintense or hyperin-
tense on T2-weighted MR images,
(c)- hyperintense central scar on T2-
Fig. 7. — Typical signs of FNH of the left lobe, at the arterial
phase, on spiral CT.
Fig. 8. — FNH of the caudate lobe, with typical signs on T2-
weighted images, associated with a small hemangioma of the
right lobe. 
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weighted MR images, (d)- tumoral
arterial enhancement, (e)- delayed
gadolinium enhancement of the
central scar on T1-weighted MR
images, (f) absence of capsule on
the pre and post-contrast MR
images (29, 30). In the rare cases in
which atypical features of FNH are
encountered on MR imaging, histo-
logical examination of the lesion is
resorted to (37).
Hepatocellular adenoma
Hepatocellular adenoma (HA) is a
benign hepatic neoplasm with a
recent decrease of prevalence. It is
associated with intake of oral con-
traceptive (OC) agents and glycogen
storage disease. The widespread 
use of low dose OCs is probably the
consequence of this low prevalence
in comparaison with previous
decades where hige dose OCs were
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Fig. 9. — Typical findings of FNH located in segment VII, on T2-WI (A), on fat suppressed T1-WI (B), after bolus injection of gadolin-
ium chelates (C), on delayed CE-fat suppressed T1-WI (D).
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commonly used. The clinical course
of HA remains usually silent until
complications occur. Surgical resec-
tion is the treatment of choice of HA
due to the associated risk of life-
threatening hemorrhage (38) and
malignant transformation (39).
Pathologically, HA is composed of
hepatocytes. Hemorrhage, necrosis,
fatty infiltration, sinusoidal dilata-
tion, and scar formation may be
observed within the lesion.
US is rather nonspecific for diag-
nosis of HA (32). Color Doppler US
enables detection of intratumoral
veins within HA (40). CT may
demonstrate hemorrhage within HA
as high attenuating areas and it may
also, though less commonly,
demonstrate fatty deposition within
HA as low attenuating areas (Fig. 11)
(41). Due to its higher sensitivity
for fat and hemorrhage, MR imaging
is superior to spiral CT in characteri-
zation of HA. On MR imaging, HA
appears hyper- or iso-intense on T1-
and hyperintense on T2-weighted
images in the majority of cases (Fig.
12). Heterogeneity of signal intensi-
ty has been considered one of the
most constant features of HA (42-44)
due to the wide range of pathologi-
cal changes which can occur within
the lesion. HA shows also variable
features as regards their vascularity
on angiography and enhancement
characteristics on dynamic contrast-
enhanced MR imaging. However,
the majority of cases appear hyper-
vascular. On MR images enhanced
with hepatobiliary contrast agents
such as manganese-DPDP, uptake of
the contrast agents by HA has been
demonstrated due to their content
of hepatocytes. Due to the frequent
absence or low content of Kupffer
cells in HA, the lesions do not
enhance after superparamagnetic
contrast agents on T2 weighted
images (Fig. 13). For this diagnostic
purpose, the role of all the imaging
modalities is to exclude FNH and to
propose surgical biopsy or HA and
resection, because HA cannot be dif-
ferentiated from HCC on imaging
alone.
From this brief survey of the com-
monly encountered benign hepatic
lesions, it is clear that MR imaging
A
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Fig. 10. — FNH associated to a small hemangioma (arrow) on T2-WI (A). On T1-WI, the both lesions are hypointense (B) and the
FNH is enhanced after MnDPDP injection with no uptake by the hemangioma (C).
Fig. 11. — Hepatocellular adenoma (HA) with hyperdense area
corresponding to hemorrhage.
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Fig. 12. — Hepatocellular adenoma of the left lobe. The lesion is isointense on T2-WI (A), hyperintense on T1-WI (B), and
hypointense on fat-suppressed T1-WI (C), and is not enhanced after bolus injection of gadolinium chelates (D). Fatty HA.
Fig. 13. — Hepatocellular adenoma on T2-WI (A) and on SPIO-
enhanced GRE T2 WI. The lesion is not enhanced due to the lack
of Kupffer cells.
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gives the clue to the correct diagno-
sis in the majority of benign hepatic
lesions by demonstration of typical
features, particularly in case of he-
mangioma and focal nodular hyper-
plasia. In the rare occasions when
benign lesions demonstrate atypical
features, or when malignant neo-
plasms mimick the typical features
of benign lesions, histological
diagnosis through biopsy or sur-
gical resection would be indicated.
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